The tachykinin NK1 receptor in the brain: pharmacology and putative functions.

After its discovery in 1931, substance P (SP) remained the only mammalian member of the family of tachykinin peptides for several decades. Tachykinins thus refer to peptides sharing the common C-terminal amino acid sequence Phe-X-Gly-Leu-Met x NH2. In recent years the family of mammalian tachykinins has grown with the isolation of two novel peptides from bovine and porcine central nervous system (CNS), neurokinin A and neurokinin B. In parallel with the identification of multiple endogenous tachykinins several classes of tachykinin receptors were discovered. The receptors described so far are named tachykinin NK1 receptor, tachykinin NK2 receptor and tachykinin NK1 receptor, respectively. The present review focuses on the pharmacology and putative function of tachykinin NK1 receptors in brain. The natural ligand with the highest affinity for the tachykinin NK1 receptor is SP itself. The C-terminal sequence is essential for activity, the minimum length of a fragment with reasonable affinity for the tachykinin NK1 receptor is the C-terminal hexapeptide. A rapid advance of knowledge was caused by development of non-peptidic tachykinin NK1 receptor antagonists. This area is under rapid development and a variety of different chemical classes of compounds are involved. Species-dependent affinities of tachykinin NK1 receptor antagonists reveal two clusters of compounds, targeting the tachykinin NK1 receptor subtype found in guinea pig, human or ferret or the one in rat or mouse, respectively. The most recently developed compounds are highly selective, enter the brain and are orally bioavailable. Distinct behavioural effects in experimental animals suggest the involvement of tachykinin NK1 receptors in nociceptive transmission, basal ganglia function or anxiety and depression. Recent clinical trials in man showed that tachykinin NK1 receptor antagonists are effective in treating depression and chemotherapy-induced emesis. Therefore, it is well possible that tachykinin NK1 receptor antagonists will be clinically used for treatment of specific CNS disorders within a short period of time.

[1]  S. Mclean Nonpeptide antagonists of the NK1 tachykinin receptor , 1996, Medicinal research reviews.

[2]  S. Nakanishi,et al.  Molecular characterization of a functional cDNA for rat substance P receptor. , 1989, The Journal of biological chemistry.

[3]  R. Hargreaves,et al.  The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. , 1993, European journal of pharmacology.

[4]  R. Hargreaves,et al.  Enantioselective inhibition of ampomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99,994 , 1994, Neuropharmacology.

[5]  A. D. Hershey,et al.  Ligand Binding Kinetics of Substance P and Neurokinin A Receptors Stably Expressed in Chinese Hamster Ovary Cells and Evidence for Differential Stimulation of Inositol 1,4,5‐Trisphosphate and Cyclic AMP Second Messenger Responses , 1992, Journal of neurochemistry.

[6]  S. Gonsalves,et al.  Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK1 receptor antagonist, in ferrets. , 1996, European journal of pharmacology.

[7]  K. Tsuchida,et al.  Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cyclic AMP cascades in transfected Chinese hamster ovary cells. , 1992, The Journal of biological chemistry.

[8]  J. Metzger,et al.  Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets , 1996, Neuropharmacology.

[9]  R. Hosoki,et al.  Pharmacological profiles of new orally active nonpeptide tachykinin NK1 receptor antagonists. , 1998, European journal of pharmacology.

[10]  S. Iversen,et al.  Behavioural effects of tachykinins and related peptides , 1986, Brain Research.

[11]  S. Nakanishi,et al.  Characterization of the substance P receptor-mediated calcium influx in cDNA transfected Chinese hamster ovary cells. A possible role of inositol 1,4,5-trisphosphate in calcium influx. , 1994, The Journal of biological chemistry.

[12]  M. Mitsuhashi,et al.  Multiple intracellular signaling pathways of the neuropeptide substance P receptor , 1992, Journal of neuroscience research.

[13]  A. Ganong,et al.  Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. , 1993, The Journal of pharmacology and experimental therapeutics.

[14]  T. Schwartz,et al.  The dual nature of the tachykinin NK1 receptor , 1997 .

[15]  A. Saria,et al.  Polypeptide-containing neurons in airway smooth muscle. , 1987, Annual review of physiology.

[16]  R. Naylor,et al.  The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret , 1996, British journal of pharmacology.

[17]  P. Andrews,et al.  The anti‐emetic effects of CP‐99,994 in the ferret and the dog: role of the NK1 receptor , 1995, British journal of pharmacology.

[18]  C. Polidori,et al.  Further Evidence that Central Tachykinin NK-1 Receptors Mediate the Inhibitory Effect of Tachykinins on Angiotensin-Induced Drinking in Rats , 1998, Peptides.

[19]  C. Whitty,et al.  Neurokinin receptor gene expression in substantia nigra: localization, regulation, and potential physiological significance. , 1995, Canadian journal of physiology and pharmacology.

[20]  P. A. Peterson,et al.  Molecular cloning of the murine substance K and substance P receptor genes. , 1992, European journal of biochemistry.

[21]  J. Blanchard,et al.  Comparative behavioural profile of centrally administered tachykinin NK1, NK2 and NK3 receptor agonists in the guinea‐pig , 1995, British journal of pharmacology.

[22]  C. Maggi Tachykinins as peripheral modulators of primary afferent nerves and visceral sensitivity. , 1997, Pharmacological research.

[23]  A. Saria,et al.  A substance P antagonist inhibits heat-induced oedema in the rat skin. , 1984, Acta physiologica Scandinavica.

[24]  M. Herkenham,et al.  Mismatches between neurotransmitter and receptor localizations in brain: observations and implications , 1987, Neuroscience.

[25]  J. Calixto,et al.  Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. , 1996, European journal of pharmacology.

[26]  C. Maggi,et al.  The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles , 1998, Neuropeptides.

[27]  R. Laufer,et al.  Characterization of a neurokinin B receptor site in rat brain using a highly selective radioligand. , 1986, The Journal of biological chemistry.

[28]  S. Iyengar,et al.  LY303870, a centrally active neurokinin-1 antagonist with a long duration of action. , 1997, The Journal of pharmacology and experimental therapeutics.

[29]  J. Krause,et al.  Both extracellular and transmembrane residues contribute to the species selectivity of the neurokinin-1 receptor antagonist WIN 51708. , 1994, Molecular pharmacology.

[30]  S. Watson,et al.  Tachykinin receptor types: Classification and membrane signalling mechanisms , 1991, Neurochemistry International.

[31]  S. Ko,et al.  2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N - methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models. , 1998, Journal of medicinal chemistry.

[32]  T. Bonner,et al.  Dopamine antagonist haloperidol decreases substance P, substance K, and preprotachykinin mRNAs in rat striatonigral neurons. , 1986, The Journal of biological chemistry.

[33]  T. Unger,et al.  Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress. , 1997, The Journal of pharmacology and experimental therapeutics.

[34]  T. Chase,et al.  The neurokinin1 receptor antagonist CP-99,994 reduces catalepsy produced by the dopamine D2 receptor antagonist raclopride: correlation with extracellular acetylcholine levels in striatum. , 1995, The Journal of pharmacology and experimental therapeutics.

[35]  R. Quirion,et al.  Pharmacological characterization and autoradiographic localization of substance P receptors in guinea pig brain , 1986, Peptides.

[36]  A. Saria,et al.  A substance P antagonist inhibits vagally induced increase in vascular permeability and bronchial smooth muscle contraction in the guinea pig. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[37]  C. Maggi,et al.  Activity of spantide I and II at various tachykinin receptors and NK-2 tachykinin receptor subtypes. , 1991, European journal of pharmacology.

[38]  T. Futami,et al.  Expression of substance P receptor in the substantia nigra. , 1998, Brain research. Molecular brain research.

[39]  K. Yoshioka,et al.  Neurotransmitter functions of mammalian tachykinins. , 1993, Physiological reviews.

[40]  J. Saper,et al.  Ineffectiveness of Neurokinin-1 Antagonist in Acute Migraine , 1997, Cephalalgia : an international journal of headache.

[41]  C. Maggi,et al.  Peripheral effects of neurokinins: functional evidence for the existence of multiple receptors. , 1987, Journal of autonomic pharmacology.

[42]  A. Saria,et al.  Substance P in sensory nerve fibres contributes to the development of oedema in the rat hind paw after thermal injury , 1984, British journal of pharmacology.

[43]  C. Maggi,et al.  The tachykinin NK1 receptor. Part I: Ligands and mechanisms of cellular activation , 1997, Neuropeptides.

[44]  J. Glowinski,et al.  Localization of tachykinin binding sites (NK1, NK2, NK3 ligands) in the rat brain , 1988, Peptides.

[45]  C. Strader,et al.  Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96,345 and RP67580. , 1992, The Journal of biological chemistry.

[46]  M. P. Turpin,et al.  Modulation of the rat mesolimbic dopamine pathway by neurokinins , 1992, Behavioural Brain Research.

[47]  L. Phebus,et al.  The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. , 1997, Life sciences.

[48]  G. Cheng,et al.  Neurokinin‐1 receptor antagonist SR140333: a novel type of drug to treat cerebral ischemia , 1997, Neuroreport.

[49]  R. Barker Substance P and Parkinson's disease: a causal relationship? , 1986, Journal of theoretical biology.

[50]  X. Hua,et al.  Capsaicin induced release of multiple tachykinins (substance P, neurokinin A and eledoisin-like material) from guinea-pig spinal cord and ureter , 1986, Neuroscience.

[51]  J. Krause,et al.  Functional expression of a novel human neurokinin-3 receptor homolog that binds [3H]senktide and [125I-MePhe7]neurokinin B, and is responsive to tachykinin peptide agonists. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[52]  L. Bristow,et al.  Chromodacryorrhea and repetitive hind paw tapping: models of peripheral and central tachykinin NK1 receptor activation in gerbils. , 1994, European journal of pharmacology.

[53]  A. Siegel,et al.  Evidence that substance P is utilized in medial amygdaloid facilitation of defensive rage behavior in the cat , 1993, Brain Research.

[54]  A. Saria,et al.  Different behavioral profiles of the non-peptide substance P (NK1) antagonists CP-96,345 and RP 67580 in Swiss albino mice in the black-and-white box , 1993, Neuroscience Letters.

[55]  I. Módy,et al.  Substance P enhances NMDA channel function in hippocampal dentate gyrus granule cells. , 1998, Journal of neurophysiology.

[56]  T. Kaneko,et al.  Immunocytochemical localization of rat substance P receptor in the striatum , 1993, Neuroscience Letters.

[57]  C. Bountra,et al.  Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. , 1993, European journal of pharmacology.

[58]  Humpel Christian,et al.  Effects of haloperidol and clozapine on preprotachykinin‐A messenger RNA, tachykinin tissue levels, release and neurokinin‐1 receptors in the striato‐nigral system , 1990 .

[59]  L. Gunne,et al.  Intranigral stimulation of oral movements by [Pro9] substance P, a neurokinin-1 receptor agonist, is enhanced in chronically neuroleptic-treated rats , 1993, Behavioural Brain Research.

[60]  P. McIntyre,et al.  Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist , 1998, British journal of pharmacology.

[61]  L. Iversen,et al.  Multiple tachykinin binding sites in peripheral tissues and in brain. , 1986, European journal of pharmacology.

[62]  C. Maggi,et al.  Tachykinin receptors and tachykinin receptor antagonists. , 1993, Journal of autonomic pharmacology.

[63]  M. Herkenham,et al.  A comparative autoradiographic study of the distributions of substance P and eledoisin binding sites in rat brain , 1986, Brain Research.

[64]  M. Kris,et al.  Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. , 1999, The New England journal of medicine.

[65]  P. Laduron,et al.  Pharmacological properties of a potent and selective nonpeptide substance P antagonist. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[66]  M. Maccoss,et al.  In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists. , 1997, European journal of pharmacology.

[67]  D. Haverstick,et al.  Striatal tachykinin gene expression regulated by interaction of D-1 and D-2 dopamine receptors. , 1989, The Journal of pharmacology and experimental therapeutics.

[68]  J. Fauchère,et al.  A structural rationale for the design of water soluble peptide-derived neurokinin-1 antagonists. , 1997, Journal of receptor and signal transduction research.

[69]  G. Seabrook,et al.  Thapsigargin blocks the mobilisation of intracellular calcium caused by activation of human NK1 (long) receptors expressed in chinese hamster ovary cells , 1993, Neuroscience Letters.

[70]  J. Marksteiner,et al.  Differential increases of neurokinin B- and enkephalin-like immunoreactivities and their mRNAs after chronic haloperidol treatment in the rat , 1992, Neuroscience Letters.

[71]  S. Macdonald,et al.  Regulation of Substance P Receptor Affinity by Guanine Nucleotide‐Binding Proteins , 1989, Journal of neurochemistry.

[72]  R. Barker Model for basal ganglia disorders , 1990, Trends in Neurosciences.

[73]  P J Elliott,et al.  Striatal tachykinin biosynthesis: regulation of mRNA and peptide levels by dopamine agonists and antagonists. , 1987, Brain research.

[74]  S. Lavielle,et al.  Highly potent substance P antagonists substituted with β-phenyl- or β-benzyl-proline at position 10 , 1994 .

[75]  N. Bowery,et al.  Effect of the tachykinin NK1 receptor antagonists, RP 67580 and SR 140333, on electrically‐evoked substance P release from rat spinal cord , 1994, British journal of pharmacology.

[76]  M. Koch,et al.  Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats , 1994, Behavioural Brain Research.

[77]  R. Hargreaves,et al.  Neurokinin-receptor antagonists: pharmacological tools and therapeutic drugs. , 1997, Canadian journal of physiology and pharmacology.

[78]  A. Saria,et al.  Simultaneous release of several tachykinins and calcitonin gene-related peptide from rat spinal cord slices , 1986, Neuroscience Letters.

[79]  R. Barker,et al.  Tachykinins, Neurotrophism and Neurodegenerative Diseases: A Critical Review on the Possible Role of Tachykinins in the Aetiology of CNS Diseases , 1996, Reviews in the neurosciences.

[80]  S. File Anxiolytic Action of a Neurokinin1 Receptor Antagonist in the Social Interaction Test , 1997, Pharmacology Biochemistry and Behavior.

[81]  Stephen P. Hunt,et al.  Altered nociception, analgesia and aggression in mice lacking the receptor for substance P , 1998, Nature.

[82]  C. Maggi,et al.  The substance P (NK1) receptor antagonist (±)-CP-96,345 causes sedation and motor impairment in Swiss albino mice in the black-and-white box behavioral paradigm , 1992, Neuroscience Letters.

[83]  F. Nantel,et al.  Pharmacology of neurokinin receptors , 1991, Biopolymers.

[84]  A. Saria,et al.  Different behavioral profiles of the non-peptide substance P (NK-1) antagonists CP-96,345 and RP 67580 , 1993, Regulatory Peptides.

[85]  Y. Minabe,et al.  The effect of the acute and chronic administration of CP 96,345, a selective neurokinin1 receptor antagonist, on midbrain dopamine neurons in the rat: A single unit, extracellular recording study , 1996, Synapse.

[86]  F. Fahrenholz,et al.  Molecular cloning of substance P receptor cDNA from guinea-pig uterus. , 1992, Biochimica et biophysica acta.

[87]  T. Schwartz,et al.  The species selectivity of chemically distinct tachykinin nonpeptide antagonists is dependent on common divergent residues of the rat and human neurokinin-1 receptors. , 1994, Molecular pharmacology.

[88]  D. Regoli,et al.  Pharmacological receptors for substance P and neurokinins. , 1987, Life sciences.

[89]  R G Hill,et al.  Distinct mechanism for antidepressant activity by blockade of central substance P receptors. , 1998, Science.

[90]  S. Iyengar,et al.  The nonpeptide NK-1 receptor antagonists LY303870 and LY306740 block the responses of spinal dorsal horn neurons to substance P and to peripheral noxious stimuli , 1998, Neuroscience.

[91]  J. Lowe,et al.  Molecular basis for the species selectivity of the substance P antagonist CP-96,345. , 1993, The Journal of biological chemistry.

[92]  A. D. Hershey,et al.  Molecular characterization of a functional cDNA encoding the rat substance P receptor. , 1990, Science.

[93]  M. Kris,et al.  Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. , 1997, Journal of the National Cancer Institute.

[94]  R. Naylor,et al.  The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret. , 1997, European journal of pharmacology.

[95]  J. Lowe,et al.  A potent nonpeptide antagonist of the substance P (NK1) receptor. , 1991, Science.

[96]  L. Pradier,et al.  Molecular determinants of the species selectivity of neurokinin type 1 receptor antagonists. , 1995, Molecular pharmacology.

[97]  R. Barker Substance P and neurodegenerative disorders. A speculative review , 1991, Neuropeptides.

[98]  M. Caron,et al.  The substance P receptor, which couples to Gq/11, is a substrate of beta-adrenergic receptor kinase 1 and 2. , 1993, The Journal of biological chemistry.

[99]  J. Metzger,et al.  An NK1 receptor antagonist affects the circadian regulation of locomotor activity in golden hamsters , 1998, Brain Research.

[100]  D. Girdlestone,et al.  RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats , 1993, Neuroscience Letters.

[101]  J. Glowinski,et al.  Quantitative autoradiographic analysis of the distribution of binding sites for [125I]Bolton Hunter derivatives of eledoisin and substance P in the rat brain , 1986, Neuroscience.

[102]  S. Nakanishi,et al.  Multiple mechanisms of arachidonic acid release in Chinese hamster ovary cells transfected with cDNA of substance P receptor. , 1994, Biochemical pharmacology.

[103]  J. Krause,et al.  Tachykinin Systems in the Spinal Cord and Basal Ganglia: Influence of Neonatal Capsaicin Treatment or Dopaminergic Intervention on Levels of Peptides, Substance P–Encoding mRNAs, and Substance P Receptor mRNA , 1992, Journal of neurochemistry.

[104]  D. Regoli,et al.  Receptors for substance P and related neurokinins. , 1989, Pharmacology.

[105]  C. Whitty,et al.  Quantitation, cellular localization and regulation of neurokinin receptor gene expression within the rat substantia nigra , 1995, Neuroscience.

[106]  N. Rajakumar,et al.  Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist , 1995, Brain Research.

[107]  J. McGinty,et al.  Lithium increases rat striatal beta- and gamma-preprotachykinin messenger RNAs. , 1989, The Journal of pharmacology and experimental therapeutics.

[108]  R. Couture,et al.  New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization. , 1988, Trends in pharmacological sciences.

[109]  J. Hey,et al.  Central antitussive activity of the NK1 and NK2 tachykinin receptor antagonists, CP‐99,994 and SR 48968, in the guinea‐pig and cat , 1997, British journal of pharmacology.

[110]  J. Fauchère,et al.  Receptors and antagonists for substance P and related peptides. , 1994, Pharmacological reviews.

[111]  C. Whitty,et al.  Neurokinin receptor mRNA localization in human midbrain dopamine neurons , 1997, The Journal of comparative neurology.

[112]  E. Kawashima,et al.  NK1 receptor expression by cholinergic interneurones in human striatum. , 1994, Neuroreport.